An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients

Cerebrovascular Diseases

Volumn 26, Issue 3, 2008, Pages 317-321

  Whyte, Ellen M ^a   Lenze, Eric J ^b   Butters, Meryl ^a   Skidmore, Elizabeth ^a   Koenig, Kris ^a   Dew, Mary Amanda ^a   Penrod, Louis ^a   Mulsant, Benoit H ^a   Pollock, Bruce G ^a   Cabacungan, Leonard ^a   Reynolds III, Charles F ^a   Munin, Michael C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apathy, stroke; Cerebrovascular accident; Cholinesterase inhibitors; Cognition, stroke; Rehabilitation, elderly

Indexed keywords

DONEPEZIL; GALANTAMINE;

AGED; APATHY; ARTICLE; ATTENTION; BRAIN FUNCTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CONVALESCENCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; FEMALE; FUNCTIONAL INDEPENDENCE MEASURE; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HOSPITAL PATIENT; HUMAN; MALE; MEMORY; MOTOR PERFORMANCE; PHYSICAL ACTIVITY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; REHABILITATION CARE; SCORING SYSTEM; STROKE PATIENT; SURVIVOR; UNSPECIFIED SIDE EFFECT;

AGED; ATTENTION; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; FEASIBILITY STUDIES; FEMALE; GALANTAMINE; HUMANS; INDANS; MALE; MIDDLE AGED; MOTIVATION; MOTOR ACTIVITY; NOOTROPIC AGENTS; PILOT PROJECTS; PIPERIDINES; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; STROKE; TREATMENT OUTCOME;

EID: 48049103455     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000149580     Document Type: Article

References (24)

1. Ballard C, Stephens S, McLaren A, Wesnes K, Kenny R: Mild cognitive impairment and vascular cognitive impairment in stroke patients. Int Psychogeriatr 2003;15(suppl 1):123-126.
2. Starkstein SE, Fedoroff JP, Price TR, Leiguarda R, Robinson RG: Apathy following cerebrovascular lesions. Stroke 1993;24:1625-1630.
3. Ozdemir F, Birtane M, Tabatabaei R, Ekuklu G, Kokino S: Cognitive evaluation and functional outcome after stroke. Am J Phys Med Rehabil 2001;80:410-415.
4. Heruti RJ, Lusky A, Dankner R, Ring H, Dolgopiat M, Barrell V, Levenkrohn S, Adunsky A: Rehabilitation outcome of elderly patients after a first stroke: effect of cognitive status at admission on the functional outcome. Arch Phys Med Rehabil 2002;83:742-749.
5. Resnick B, Zimmerman SI, Magaziner J, Adelman A: Use of the apathy evaluation scale as a measure of motivation in elderly people. Rehabil Nurs 1998;23:141-147.
6. Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo CA, Kumar D, Pratt RD: Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323-2332.
7. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD: Donepezil in vascular dementia. A randomized, placebo-controlled study. Neurology 2003;61:479-486.
8. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-1290.
9. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G: Cholinesterase inhibitors as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients. Am J Alzheimers Dis Other Demen 2004;19:333-339.
10. Almkvist O, Jelic V, Amberla K, Hellstrom-Lindahl E, Meurling L, Nordberg A: Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord 2001;12:22-32.
11. Kaufer DI: Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders. Curr Psychiatry Rep 1999;1:78-84.
12. Cummings JL, Kaufer D: Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996;47:876-883.
13. Shapiro AM, Benedict RH, Schretlen D, Brandt J: Construct and concurrent validity of the Hopkins Verbal Learning Test - revised. Clin Neuropsychol 1999;13:348-358.
14. Wechsler D: Wechsler Adult Intelligence Scale - III. San Antonio, The Psychological Corporation, 1996.
15. Royall DR, Mahurin RK, Gray KF: Bedside assessment of executive cognitive impairment: the Executive Interview. J Am Geriatr Soc 1992;40:1221-1226.
16. Guide for the Uniform Data Set for Medical Rehabilitation (Adult FIM). Buffalo, State University of New York at Buffalo, 1993.
17. Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991;38:143-162.
18. Linacre JM, Heinemann AW, Wright BD: The structure and stability of the Functional Independence Measure. Arch Phys Med Rehabil 1994;75:127-132.
19. Brown H, Prescott R: Applied Mixed Models in Medicine. Chichester, Wiley & Sons, 1999.
20. Granger CV, Cotter AC, Hamilton BB, Fiedler RC: Functional assessment scales: a study of persons after stroke. Arch Phys Med Rehabil 1993;74:133-138.
21. Berthier ML, Pujol J, Gironell A, Kulisevsky J, Deus J, Hinojosa J, Soriano-Mas C: Beneficial effect of donepezil on sensorimotor function after stroke. Am J Phys Med Rehabil 2003;82:725-729.
22. Nadeau SE, Behrman AL, Davis SE, Reid K, Wu SS, Stidham BS, Helms KM, Gonzalez Rothi LJ: Donepezil as an adjuvant to constraint-induced therapy for upper-limb dysfunction after stroke: an exploratory randomized clinical trial. J Rehabil Res Dev 2004;41:525-534.
23. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145.
24. Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-2268.